Therapy Areas: Respiratory
Actelion Pharmaceuticals reveals results of first randomised controlled trial in portopulmonary hypertension
18 September 2018 -

Switzerland-based Actelion Pharmaceuticals has revealed results of the first randomised controlled trial of Opsumit (macitentan) in treating portopulmonary hypertension (PoPH), it was reported yesterday.

The results indicated that Opsumit significantly improved pulmonary vascular resistance compared with placebo, meeting the primary endpoint of the study. Presented as a late-breaking oral presentation at the European Respiratory Society meeting in France, the portopulmonary hypertension Treatment with macitentan, a randomised clinical trial that indicated the safety of macitentan in portopulmonary hypertension, was consistent with that observed in previous clinical trials.

The product is an orally active endothelin receptor antagonist that is presently approved in the US and Europe for the treatment of pulmonary arterial hypertension.

Login
Username:

Password: